Opinion

Video

Predictors of Immunotherapy Response in Limited and Extensive SCLC

Afshin Dowlati, MD, explores which patients with small cell lung cancer experience the most significant benefit from immunotherapy in both limited and extensive stage disease, while also examining potential clinical or molecular characteristics that could serve as predictors of prolonged survival.

  1. How do we advance the field on which patients with SCLC derive the greatest benefit from IO in both limited stage and extensive stage disease?
  2. Do we yet know which clinical or molecular characteristics might predict extended survival in ES-SCLC, such as platinum sensitivity or PD-L1 expression?
  3. For those who experience extended survival, do you continue immunotherapy and how long is that interval?
Related Videos
3 KOLs are featured in this series.
3 KOLs are featured in this series.
Video 8 - 2 KOLs are featured in, "Emerging Trials in the Management of HR+/HER2- mBC"
Video 7 - 2 KOLs are featured in, "Adverse Event Data and Management for Optimal Quality of Life in HR+/HER2- mBC"
4 KOLs are featured in this series
2 KOLs are featured in this series
2 KOLs are featured in this series
5 KOLs are featured in this peer exchange
5 KOLs are featured in this peer exchange
A panel of 5 experts on breast cancer